title: A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
abstract: The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease. Trastuzumab, as a second line treatment, has shown a 15% objective response rate in patients with metastatic breast cancer. We present the case of a patient with two breast tumours, the second of more aggressive characteristics, with negative hormone receptors and c-erb-B2 +++, and with few therapeutic options due to her hepatic insufficiency secondary to metastatic disease; she was administered herceptin as monotherapy, and she had a complete clinical response. Trastuzumab has revolutionised the management of patients with metastatic breast cancer and Her-2- neu overexpression. Its combination with chemotherapy agents achieves a synergic activity.
authors.affiliation: Department of Medical Oncology, Elche University General Hospital, Eche, Alicante, Spain. smacia@tiscali.es
authors.forename: Sonia
authors.initials: S
authors.lastname: Maciá Escalante
authors.forename: Alvaro
authors.initials: A
authors.lastname: Rodríguez Lescure
authors.forename: Vanesa
authors.initials: V
authors.lastname: Pons Sanz
authors.forename: Natividad
authors.initials: N
authors.lastname: Martínez Banaclocha
authors.forename: Carmen
authors.initials: C
authors.lastname: Guillén Ponce
authors.forename: Alfredo
authors.initials: A
authors.lastname: Carrato Mena
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D017567:Karnofsky Performance Status; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D008207:Lymphatic Metastasis; D015411:Mastectomy, Modified Radical; D008727:Methotrexate / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D000068878:Trastuzumab